217 related articles for article (PubMed ID: 20959068)
41. Predictive and prognostic value of preoperative serum tumor markers is EGFR mutation-specific in resectable non-small-cell lung cancer.
Jiang R; Wang X; Li K
Oncotarget; 2016 May; 7(18):26823-36. PubMed ID: 27072585
[TBL] [Abstract][Full Text] [Related]
42. Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients.
Zhang S; He L; Dai N; Guan W; Shan J; Yang X; Zhong Z; Qing Y; Jin F; Chen C; Yang Y; Wang H; Baugh L; Tell G; Wilson DM; Li M; Wang D
Oncotarget; 2016 Nov; 7(47):77482-77494. PubMed ID: 27813497
[TBL] [Abstract][Full Text] [Related]
43. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
Nisman B; Heching N; Biran H; Barak V; Peretz T
Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
[TBL] [Abstract][Full Text] [Related]
44. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
[TBL] [Abstract][Full Text] [Related]
45. CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.
Sone K; Oguri T; Nakao M; Kagawa Y; Kurowaka R; Furuta H; Fukuda S; Uemura T; Takakuwa O; Kanemitsu Y; Ohkubo H; Takemura M; Maeno K; Ito Y; Sato H; Muramatsu H; Niimi A
Anticancer Res; 2017 Feb; 37(2):935-939. PubMed ID: 28179355
[TBL] [Abstract][Full Text] [Related]
46. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
Jiang ZF; Wang M; Xu JL
Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
[TBL] [Abstract][Full Text] [Related]
47. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer.
Takano A; Ishikawa N; Nishino R; Masuda K; Yasui W; Inai K; Nishimura H; Ito H; Nakayama H; Miyagi Y; Tsuchiya E; Kohno N; Nakamura Y; Daigo Y
Cancer Res; 2009 Aug; 69(16):6694-703. PubMed ID: 19679554
[TBL] [Abstract][Full Text] [Related]
48. The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer.
Ustaalioglu BB; Bilici A; Ercan S; Seker M; Orcun A; Gumus M
Med Oncol; 2013 Jun; 30(2):551. PubMed ID: 23536001
[TBL] [Abstract][Full Text] [Related]
49. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].
Hang ZQ; Zheng MF; Huang JH
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951
[TBL] [Abstract][Full Text] [Related]
50. Prognostic Significance of Serum miR-22, miR-125b, and miR-15b in Non-Small Cell Lung Cancer Patients.
Shi GL; Zhang XY; Chen Y; Ma S; Bai WQ; Yin YJ
Clin Lab; 2020 Jun; 66(6):. PubMed ID: 32538046
[TBL] [Abstract][Full Text] [Related]
51. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients.
Zhang L; Liu D; Li L; Pu D; Zhou P; Jing Y; Yu H; Wang Y; Zhu Y; He Y; Li Y; Zhao S; Qiu Z; Li W
BMC Cancer; 2017 Feb; 17(1):96. PubMed ID: 28152979
[TBL] [Abstract][Full Text] [Related]
52. Serum CYFRA 21-1 Level as a Prognostic Marker for Extensive Disease Small Cell Lung Cancer.
Nakao M; Kinoshita R; Kuriyama M; Kiyotoshi H; Sugihara M; Takeda N; Ohtakara K; Muramatsu H
Anticancer Res; 2024 Feb; 44(2):845-851. PubMed ID: 38307561
[TBL] [Abstract][Full Text] [Related]
53. Circulating long non-coding RNA AFAP1-AS1 is a potential diagnostic biomarker for non-small cell lung cancer.
Li W; Li N; Kang X; Shi K
Clin Chim Acta; 2017 Dec; 475():152-156. PubMed ID: 29080690
[TBL] [Abstract][Full Text] [Related]
54. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
Li R; Li R; Wang Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
[TBL] [Abstract][Full Text] [Related]
55. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
[TBL] [Abstract][Full Text] [Related]
56. Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution.
He X; Zhang Y; Ma Y; Zhou T; Zhang J; Hong S; Sheng J; Zhang Z; Yang Y; Huang Y; Zhang L; Zhao H
Medicine (Baltimore); 2016 Aug; 95(31):e4176. PubMed ID: 27495021
[TBL] [Abstract][Full Text] [Related]
57. Combination of serum miRNAs with Cyfra21-1 for the diagnosis of non-small cell lung cancer.
Zhou C; Chen Z; Dong J; Li J; Shi X; Sun N; Luo M; Zhou F; Tan F; He J
Cancer Lett; 2015 Oct; 367(2):138-46. PubMed ID: 26213369
[TBL] [Abstract][Full Text] [Related]
58. Positive reactions for both Cyfra21-1 and CA125 indicate worst prognosis in non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Yamamoto N; Iida T
Anticancer Res; 2003; 23(3C):2869-74. PubMed ID: 12926125
[TBL] [Abstract][Full Text] [Related]
59. Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib.
Chen F; Luo X; Zhang J; Lu Y; Luo R
Med Oncol; 2010 Sep; 27(3):950-7. PubMed ID: 19830603
[TBL] [Abstract][Full Text] [Related]
60. Predictive value of serum SCCA and CYFRA21-1 levels on radiotherapy efficacy and prognosis in patients with non-small cell lung cancer.
Chen F; Zhang X
Biotechnol Genet Eng Rev; 2023 May; ():1-10. PubMed ID: 37153975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]